[September 05, 2011]

Research and Markets: Panic Disorders Pipeline Review, Q2 2011 - Identify & Review Panic Disorders Products Under Development

Research and Markets (http://www.researchandmarkets.com/research/55b244/panic_disorders) has announced the addition of Global Markets Direct's new report "Panic Disorders - Pipeline Review, Q2 2011" to their offering.

Global Markets Direct's, 'Panic Disorders - Pipeline Review, Q2 2011', provides an overview of the Panic Disorders therapeutic pipeline. This report provides information on the therapeutic development for Panic Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also rviews key players involved in the therapeutic development for Panic Disorders.

'Panic Disorders - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:

• A snapshot of the global therapeutic scenario for Panic Disorders.
• A review of the Panic Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Panic Disorders pipeline on the basis of therapeutic class, route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy:

• Identify and understand important and diverse types of therapeutics under development for Panic Disorders.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Panic Disorders pipeline depth and focus of Panic Disorders therapeutics.

For more information visit http://www.researchandmarkets.com/research/55b244/panic_disorders

[ Back To TMCnet.com's Homepage ]